https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-75182004031100007
NUEVAS PERSPECTIVAS EN LA SELECCIÓN Y EVALUACIÓN DE PROBIÓTICOS

Rev Chil Nutr Vol. 21, Suplemento N°          1, Noviembre 2004, pásg: 184-185

Carta al Editor

NUEVAS PERSPECTIVAS EN          LA SELECCIÓN Y EVALUACIÓN DE PROBIÓTICOS

NEW PERSPECTIVES IN THE SELECTION AND          EVALUATION OF PROBIOTICS

 

Nava GM, Davila V.

Facultad de Medicina Veterinaria y Zootecnia,          Universidad Autonóma de México. Mexico 04510.

En el volumen 31 de la Revista Chilena          de Nutrición, Acevedo et al., (2004) describen el análisis          microbiológico de distintas presentaciones comerciales de cultivos          probióticos de Saccharomyces boulardii (1). En          este estudio, se evaluó el grado crecimiento específico          de esta cepa bacteriana benéfica. Al igual que en el reporte de          Acevedo et al., (2004), algunos investigadores consideran al nivel de          crecimiento bacteriano como una característica importante de los          probióticos efectivos (1). Sin embargo, existen          otras variables microbiológicas que determinan la efectividad de          las terapias probióticas.

En los últimos años, el uso          de probióticos en la profilaxis y terapia de enfermedades gastrointestinales          has sido objeto de gran interés y de controversia científica.          Hoy en día se reconoce la importancia y possible eficacia de la          terapia biótica (probióticos y prebióticos) como          herramienta médica en el tratamiento de enfermedades digestivas.          El uso de próbioticos se ha recomendado en casos de syndrome de          inflamación intestinal, infecciones intestinales bacterianas y          virales, entre otras (2,3,4,5,6).          Recientes publiciones sugieren que la restauración de las comunidades          microbianas endógenas, es la solución a varios padecimientos          de la mucosa intestinal e inclusó vaginal (5,6).

No existe ninguna duda de la importancia          de la microbiota intestinal para mantener la salud e integridad de la          mucosa intestinal. Sin embargo, se necesita informacion científica          y clinica para aplicar conceptos de ecología bacteriana intestinal          en la formulación, selección y recomendación de probióticos          en la práctica profesional. Actualmente, existen una gran cantidad          de productos probióticos disponibles en el mercado. La cepas bacterianas          y cantidad de microorganismos utilizados en cada formulación de          productos varia considerablemente. Esta tendencia comercial y el impacto          monetario que esto implica, ha generado que el mercado se encuentre inundado          de productos de diferentes calidades. Desafortunadamente, sin una regulación          científica o federal, la efectividad de los productos disponibles          es variente y dificilmente se podra hacer alguna recomendación          médica de productos terapéuticos eficientes (7).

La recomendación de productos bióticos          para la terapia de enfermedades gastrointestinales debe considerar no          solo la actividad biológica de las bacterias benéficas incluidas          en la formulación, sino además, las condiciones fisiopatológicas          de los pacientes. En la ultima década, se han descrito diferentes          características deseadas en la selección de bacterias benéficas          para la formulación de probióticos. Las factores más          asociados con la selección de bacterias probioticas incluye, grado          de colonización de la mucosa intestinal, actividad antimicrobiana          contra patogenos gastrointestinales, producción de sustancias bactericidas          y facilidad para adaptar esta tecnología en la producción          a escala comercial (8,9,10,11).          Adicionalmente, se debe practicar un estudio clínico a cada paciente          antes de recomendar cualquier tratamiento. El probiótico debe ser          el apropiado para las condiciones patológicas por las que cursa          el individuo.

Recientes estudios has reportado resultados          no significativos con el uso de probióticos en el tratamiento de          enfermedades gastrointestinales. Sin embargo, en ninguno de estos trabajos          se evaluó las características biológicas y protectoras          de las cepas benéficas utilizadas. Debemos frenar el uso de probióticos          como panacea y enfocarnos más al estudio de la ecología          intestinal para recomendar una medicación adecuada. 

 

References

1. Acevedo CG. Romero J,          Espejo R. Actividad de distintas presentaciones comerciales de saccharomyces          boulardii. Rev Chil. Nutr 2004; 31:33-38.         [ Links ]2. Kruis W. Antibiotics          and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004;          20:75-8.        [ Links ]3. Marteau P, Lepage P,          Mangin I, Suau A, Doré J, Pochart P, Seksik P. Gut flora and inflammatory          bowel disease. Aliment Pharmacol Ther 2004; 20:18-23.        [ Links ]4. Barbara G, De Giorgio          R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological          mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20          (Suppl. 2):1-9.        [ Links ]5. Sartor RB. Therapeutic          manipulation of the enteric microflora in inflammatory bowel diseases:          antibiotics, probiotics, and Prebiotics. Gastroenterology. 2004;126:1620-33.        [ Links ]6. Saggioro A. Probiotics          in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl          6):S104-6.        [ Links ]7. Jeavons HS. Prevention          and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.          JOGNN 2003;32:287-96.        [ Links ]8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

2. Kruis W. Antibiotics          and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004;          20:75-8.        [ Links ]3. Marteau P, Lepage P,          Mangin I, Suau A, Doré J, Pochart P, Seksik P. Gut flora and inflammatory          bowel disease. Aliment Pharmacol Ther 2004; 20:18-23.        [ Links ]4. Barbara G, De Giorgio          R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological          mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20          (Suppl. 2):1-9.        [ Links ]5. Sartor RB. Therapeutic          manipulation of the enteric microflora in inflammatory bowel diseases:          antibiotics, probiotics, and Prebiotics. Gastroenterology. 2004;126:1620-33.        [ Links ]6. Saggioro A. Probiotics          in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl          6):S104-6.        [ Links ]7. Jeavons HS. Prevention          and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.          JOGNN 2003;32:287-96.        [ Links ]8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

3. Marteau P, Lepage P,          Mangin I, Suau A, Doré J, Pochart P, Seksik P. Gut flora and inflammatory          bowel disease. Aliment Pharmacol Ther 2004; 20:18-23.        [ Links ]4. Barbara G, De Giorgio          R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological          mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20          (Suppl. 2):1-9.        [ Links ]5. Sartor RB. Therapeutic          manipulation of the enteric microflora in inflammatory bowel diseases:          antibiotics, probiotics, and Prebiotics. Gastroenterology. 2004;126:1620-33.        [ Links ]6. Saggioro A. Probiotics          in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl          6):S104-6.        [ Links ]7. Jeavons HS. Prevention          and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.          JOGNN 2003;32:287-96.        [ Links ]8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

4. Barbara G, De Giorgio          R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological          mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20          (Suppl. 2):1-9.        [ Links ]5. Sartor RB. Therapeutic          manipulation of the enteric microflora in inflammatory bowel diseases:          antibiotics, probiotics, and Prebiotics. Gastroenterology. 2004;126:1620-33.        [ Links ]6. Saggioro A. Probiotics          in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl          6):S104-6.        [ Links ]7. Jeavons HS. Prevention          and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.          JOGNN 2003;32:287-96.        [ Links ]8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

5. Sartor RB. Therapeutic          manipulation of the enteric microflora in inflammatory bowel diseases:          antibiotics, probiotics, and Prebiotics. Gastroenterology. 2004;126:1620-33.        [ Links ]6. Saggioro A. Probiotics          in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl          6):S104-6.        [ Links ]7. Jeavons HS. Prevention          and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.          JOGNN 2003;32:287-96.        [ Links ]8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

6. Saggioro A. Probiotics          in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl          6):S104-6.        [ Links ]7. Jeavons HS. Prevention          and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.          JOGNN 2003;32:287-96.        [ Links ]8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

7. Jeavons HS. Prevention          and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.          JOGNN 2003;32:287-96.        [ Links ]8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

8. van der Wielen PW, Lipman          LJ, van Knapen F, Biesterveld S. Competitive Exclusion of Salmonella enterica          serovar Enteritidis by Lactobacillus crispatus and Clostridium lactatifermentans          in a Sequencing Fed-Batch Culture. Appl Environ Microbiol 2002;68: 555-559.        [ Links ]9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

9. Nava GM, Pixley C, Jarquin          RL, Sartor CD, Vicente JL, Tellez G, Donoghue AM, Hargis BM, Reduction          of Salmonella enteritidis infection by therapeutic administration of Lactobacillus          probiotic culture. Poult Sci 2004;83(Suppl. 1):108.        [ Links ]10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

10. La Ragione RM, Narbad          A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii          FI9785 for use as a defined competitive exclusion agent against bacterial          pathogens in poultry. Lett Appl Microbiol 2004,38:197-205.        [ Links ]11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

11. Mead GC. Prospects          for 'competitive exclusion' treatment to control salmonellas and other          foodborne pathogens in poultry. Vet J. 2000;159:111-23.        [ Links ]The author has not competing interests 

The author has not competing interests